4.5 mg
Trade Name
Ozawade
Film-coated tablet
Request Type
New Registration
Drug Type
NCE
Approval Date
SFDA Approved Use
Pitolisant is indicated to improve wakefulness and reduce excessive daytime sleepiness (EDS) in adult patients with obstructive sleep apnoea (OSA) whose EDS has not been satisfactorily treated by, or who have not tolerated, OSA primary therapy, such as continuous positive airway pressure (CPAP). In addition to the treatment of narcolepsy with or without cataplexy in adults, adolescents and children from the age of 6 years.